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Outcomes after endovascular intervention for
chronic critical limb ischemia
Monica S. O’Brien-Irr, MS, RN,a Hasan H. Dosluoglu, MD,a Linda M. Harris, MD,a,b and
Maciej L. Dryjski, MD, PhD,a,b Buffalo, NY
Objective: This study evaluated outcomes after endovascular intervention (EVI) for chronic critical limb ischemia (CLI)
by Rutherford category (RC) 4, rest pain; and 5, tissue loss.
Methods: The medical records of all EVI performed for RC-4 to RC-5 by vascular surgeons at a single institution during
a 3-year period were reviewed for sustained clinical success (SCS), defined as Rutherford improvement score (RIS) 2,
without target extremity revascularization (TER). The RC-5 group was evaluated for patency until healing and healing
<4 months without recurrence or new ulceration. Secondary sustained clinical success (SSCS) was a RIS of 2with TER.
The RC-5 group was evaluated for patency until healing and healing at any time during follow-up, without recurrent or
new ulceration. Significance was established at the 0.05 level.
Results: Of 106 EVI performed for CLI, 78 (74%) were RC-5. There were 39 (37%) men. Mean age was 73  12 years.
Mean follow-up was 19 months (range, 1-44 months). RC-5 patients were significantly more likely than RC-4 to be
diabetic (58% vs 32%; P  .020), dialysis dependent (14% vs 0%; P  .036), and to require distal EVI (53% vs 29%; P 
.029). RC-4 patients were more likely to be current smokers (57% vs 32%; P  .023). At 24 months, survival was
comparable, with RC-4 at 84%  8% vs RC-5 at 62%  7% (P  .09), but limb salvage was significantly better for RC-4
(100%) vs RC-5 (83%  4%; P  .026), as was SCS (48% vs 21%; P  .006) and SSCS (85% vs 39%; P < .001).
Independent predictors of failed SSCS were diabetes (odds ratio [OR], 2.83; 95% confidence interval [CI], 1.07-7.46;
P  .036), congestive heart failure (CHF; OR, 3.62; 95% CI, 1.19-10.99; P  .023), and RC-5 (OR, 5.5; 95% CI,
2.4-30.3; P .001). SSCS was 94% in RC-4 patients without diabetes mellitus (DM) or CHF and 10% in RC-5 with DM
or CHF (P < .001) but improved to 67% in RC-5 when neither CHF nor DM were present (P  .004).
Conclusions:RC-4 have fewer comorbidities, less advanced ischemia, and better outcome than RC-5. These groups should
be evaluated individually. Limb salvage was acceptable, yet early wound healing without TER (SCS) occurred in only
21%. RC-5, DM, and CHF were predictors of poor SSCS. Careful selection of patients should improve outcome. (J Vasc
Surg 2011;53:1575-81.)
u
c
w
r
c
n
q
h
t
C
a
c
p
t
w
g
c
a
s
s
e
p
a
cDuring the past decade, dramatic changes have oc-
curred in the surgical management of patients with chronic
critical limb ischemia (CLI) as well as the manner in which
we define clinical success after revascularization. Endovas-
cular intervention (EVI) for treatment of CLI has increased
prolifically and is now performed more commonly than
lower extremity bypass. Amputation rates have declined
25% during this time.1
Although this is certainly a positive development, limb
salvage and other outcomes, such as patency, reinterven-
tion, and survival, which have been customarily used to
evaluate clinical success, are recognized as inadequate mea-
sures because they afford only a snapshot of the vast issues
that confront patients with CLI. These individuals, partic-
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doi:10.1016/j.jvs.2011.01.068larly patients with tissue loss, require frequent ongoing
are of their extremity, are subject to prolonged periods of
ound healing, and experience a subsequent need for
eintervention. Accordingly, some have suggested that a
omprehensive evaluation of success requires contempora-
eous evaluation of traditional parameters, along with
uality-of-life measures such as symptom relief, wound
ealing, and functional status.2,3
Studies that have incorporated tandem evaluation of
hese measures have reported less-than-optimal outcomes.
linical success after EVI for CLI has ranged between 31%
nd 59%.4-6 Unfortunately, operational definitions of suc-
ess and the study populations have varied, making com-
arative analysis difficult. Moreover, the term CLI is rou-
inely used in clinical practice and research to designate a
ide array of symptoms from ischemic rest pain to gan-
rene. Yet, comorbidities, severity of ischemia, and out-
omes probably differ significantly across these diagnoses,
s do the measures that appropriately define success. Limb
alvage and wound healing are appropriate indicators of
uccess for those with tissue loss but may be less sensitive or
ven unsuitable measures (ie, healing) for those with rest
ain. This becomes particularly important when patients
re evaluated as a cohort under the CLI umbrella, because
omposition of the sample likely affects results.
Findings may be artificially elevated among studies
eavily weighted with patients in Rutherford class (RC) 4
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June 20111576 O’Brien-Irr et aland visa versa for those in RC-5. Clinical success of 59% to
69% was reported in 1-year in studies that evaluated pa-
tients with rest pain and tissue loss collectively,5,6 in con-
trast to 37% in a study that evaluated tissue loss only.4
Understanding similarities and differences between pa-
tients with rest pain and tissue loss is critical to achieving
outcome analysis that is both appropriate and valid. The
Rutherford classification allows for comprehensive analysis
of CLI by using objective clinical data to differentiate
ischemic rest pain (RC-4) from tissue loss (RC 5-6).7 The
purpose of this investigation was to evaluate both conven-
tional and patient-oriented outcomes following EVI for
CLI by patients with RC-4 to RC-5.
METHODS
This was a retrospective review of hospital medical
records and physician office records for all patients who
underwent infrainguinal EVI for CLI by two vascular sur-
geons at one university-affiliated hospital between January
2005 and June 2008. The variables evaluated were:
● gender, age at time of procedure, RC,7 and ankle-
brachial index (ABI);
● comorbidities, including coronary artery disease (myo-
cardial infarction3 months from EVI), diabetes melli-
tus (use of insulin or oral agent), end-stage renal disease
(ESRD; dialysis-dependence), stroke (cerebrovascular
accident), hypertension, congestive heart failure (CHF),
chronic obstructive pulmonary disease, hyperlipidemia
(use of oral agent or lifestyle modification);
● smoking, defined as smoking within the previous 5
years;
● TransAtlantic Intersociety Consensus (TASC) II clas-
sification8 (TASC I classification for infrapopliteal le-
sions was used for infragenicular EVI)9;
● type of procedure performed, including atherectomy,
angioplasty, stent; and
● level of procedure recorded as supragenicular or
infragenicular.
Patients were monitored for 2 years for survival, limb
salvage, sustained clinical success (SCS), and secondary
SCS (SSCS). Patients were routinely evaluated with an
office visit and ABI evaluation at 1, 3, 6, 12, 18, and 24
months after EVI. A duplex ultrasound evaluation was
routinely completed at 3, 6, 12, and 24months and also for
worsening of symptoms or a drop in ABI0.10, which was
followed by angiography if reintervention was considered.
The RC-5 patients were seen on an as-needed basis for
wound assessment and management.
Definitions of clinical success were adapted from re-
porting standards recommended by Diehm et al,10 who
indicated that patients with CLI demonstrate healing of all
wounds and resolution of ischemic rest pain. Variations of
this definition to incorporate need for subsequent reinter-
vention have been used previously by others as well as
ourselves.5,6 In this study, we not only evaluated target
extremity revascularization (TER) but also included time prames for healing and parameters for recurrence in an
ffort to fully address issues of wound closure.
SCS was defined as a Rutherford improvement score of
2: still symptomatic but with improvement in lesion
ategory (may have claudication but not CLI); ABI in-
reased by at least 0.10, but not normalized,7 without
ER, recurrent or new ulceration. TER was defined as any
psilateral reintervention other than intentionally staged
rocedures (ie, 6 weeks of the initial EVI). For RC-5
atients, SCS was defined as healing4months of EVI and
atency until healing. The time frame for healing was
elected from results by Nicoloff et al,3 who indicated that
ealing of all wounds after infrainguinal bypass for limb
alvage required a mean of 4 months.3
When considering patency until healing, any EVI that
esulted in an increase in ABI by 0.10 and was maintained
ntil time of healing was considered successful. Conversely,
ailure to improve ABI by0.10 or a drop in ABI, associated
ith duplex imaging or angiographic evidence of restenosis
efore the point of healing, was considered unsuccessful.
SCCS was defined as a Rutherford improvement score
f 2.7 TER was allowable, as was delayed healing 4
onths after EVI (ie, healing at any time during follow-
p), and patency was required until healing, without recur-
ent or new ulceration.
The Rutherford classification was used to evaluate the
ntire sample, along with subgroup comparison.7 With the
xception of survival, for which analysis was completed by
able I. Clinical features of Rutherford class 4 (RC-4)
nd 5 (RC-5) patients
ndicator RC- 4 RC- 5 Pa
emale gender, % 71 60 .273
ge, mean  SD, y 72  13.0 74  12 .580
re-EVI ABI, mean  SD 0.56  0.14 0.36  0.10 .001
AD (MI 3 months
from EVI), % 11 21 .236
iabetes mellitus, % 32 58 .002
enal failure, % 0 14 .036
erebrovascular accident, % 14 22 .377
ongestive heart failure, % 25 34 .392
ypertension, % 85 95 .106
yperlipidemia, % 59 57 .809
urrent smoker, % 57 32 .023
OPD, % 18 22 .638
ASC C or D, % 91 95 .413
ultiple segments
treated, % 57 69 .264
ndex procedure, % .353
Angioplasty with stent 41 44
Angioplasty without
stent 52 39
Atherectomy 7 17
Infragenicular
intervention, % 29 53 .029
AD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ase; EVI, endovascular intervention; MI, myocardial infarction; SD, stan-
ard deviation; TASC, TransAtlantic InterSociety Consensus.
Values of P  .05 are significant.atient, outcome was evaluated by procedure. When mul-
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Volume 53, Number 6 O’Brien-Irr et al 1577tiple segments were treated during the same EVI, the most
distal intervention was identified as the index procedure.
Statistical analysis was completed with SPSS 17 soft-
ware (SPSS Inc, Chicago Ill). Bivariate analysis was com-
pleted by 2 test. Multivariate analysis with the likelihood
ratio was completed for variables that were statistically
significant by bivariate analysis. Sustained clinical success
and SSCS were evaluated by 2 test. Survival and limb
salvage were evaluated by Kaplan-Meier analysis. Statistical
significance was reported at 0.05.
RESULTS
A total of 106 procedures were completed in 99 pa-
tients (65% women). The mean age was 73  19 years.
Twenty-eight procedures (26%) were completed for RC-4
and 78 (74%) for RC-5. Ninety-four percent of vessels
treated were for TASC class C (53.6%) or D (37.1%)
disease. Angioplasty with (42.3%) or without stenting
(43.3%) was most frequently performed. Atherectomy was
completed in 14.4%. Treatment of multiple segments was
common (65.7%). All procedures were infrainguinal. The
index procedure was infragenicular in 45.7% of interven-
tions. Stenting was more common among supragenicular
EVI (50%) than in infragenicular (33%), but this was not
Fig 1. Survival at 24 months in Rutherford class 4
intervention. EVI, Endovascular intervention.significantly different (P  .192). fSimilarities and differences by Rutherford classification
re reported in Table I. The RC-5 patients were signifi-
antly more likely than RC-4 patients to have ESRD, DM,
lower ABI at presentation, and to undergo distal inter-
ention. RC-4 patients were more likely to be current
mokers.
The mean follow-up was 19 13 months (range, 1-44
onths). At 24 months, survival was 84%  8% for RC-4
nd 62%  7% for RC-5, which was not significantly
ifferent (P  .09; (Fig 1); limb salvage was 88% for the
ntire cohort and 100% for RC-4, which was significantly
etter than the 83% 4% for RC-5 (P .026; Fig 2). TER
as completed in 38% of the sample. Although this was
erformed more commonly in RC-4 (46%) than in RC-5
atients (35%), the difference was not statistically signifi-
ant (P  .29). Wound healing occurred in 50% of RC-5
atients, but was delayed 4 months in 44%. The mean
ime for complete wound closure was 7 months; how-
ver, 78% of patients who achieved prompt healing (4
onths) did so by 2 months. Recurrent ulceration de-
eloped in 17%.
SCS for the entire CLI cohort was 27% and SSCS was
2%. Clinical outcomes were significantly better for RC-4
han RC-5 patients. SCS was 48% for RC-4 patients vs 21%
4) and 5 (RC-5) patients treated with endovascular(RC-or RC-5 (P .006), and SSCSwas 85% vs 39% (P .001),
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June 20111578 O’Brien-Irr et alrespectively. The influence of comorbidities on outcome by
bivariate analysis is presented in Table II. No comorbidities
were associated with failed SCS or SSCS in RC-4 patients,
but DM was associated with failed SCS and SSCS in RC-5
patients. Paradoxically, SSCS was statistically lower among
RC-5 patients who were nonsmokers or had a remote
smoking history than current smokers or those with a
recent history (31% vs 57%, P  .05) However, smokers
were less likely than nonsmokers to have DM (47.8% vs
62.5%, P  .241) or CHF (20.8% vs 40.8%, P  .09).
When the entire cohort was examined, DM, ESRD, and
RC-5 were associated with poorer SCS. SSCS was statisti-
cally poorer among RC-5 patients, DMpatients, those with
CHF, and paradoxically, among nonsmokers. Again, smok-
ers were less likely than nonsmokers to have DM (41% vs
56.7%, P  .13) or CHF (20% vs 39.3%, P  .04).
DMwas an independent predictor of failed SCS among
RC-5 patients, whereas DM and CHF were both indepen-
dent predictors of failed SSCS for this group. Only 10% of
RC-5 patients with DM and CHF attained SSCS. This
increased to 33% when only one risk factor was present (ie,
CHF or DM) and to 67% in RC-5 patients who had neither
CHF nor DM (P  .004).
When the entire CLI sample was considered, RC-5 was
an independent predictor for failed SCS, whereas DM,
CHF, and RC-5 were all independent predictors of failed
SSCS (Table III). Secondarily sustained clinical success was
Fig 2. Limb salvage at 24 months in Rutherford class
intervention. EVI, Endovascular intervention.94% among patients with no independent risk factors nRC-4 without DM or CHF) but only 10% when every
ndependent predictor was present (RC-5 with DM and
HF, P  .001).
ISCUSSION
EVI for treatment of lower extremity CLI has ex-
anded rapidly in the past decade. However, rigorous
rocedurally related and patient-oriented outcome evalua-
ion has lagged behind, particularly research in which con-
omitant analysis of outcome measures has been used.
tudies that have collectively evaluated patients with rest
ain or tissue loss have likely produced results that are
mprecise, and those that have evaluated tissue loss solely
ave provided insight for only a portion of the CLI popu-
ation. Understanding similarities and differences between
utherford categories is critical to the formation of direc-
ives for guiding treatment decisions.
Survival at 24 months was 84% for RC-4 patients and
2% for RC-5 patients, which was reasonable (P  .09),
emonstrating the need for revascularization that is both
ffective and durable. When limb salvage was considered as
he exclusive determinant of clinical success, outcome was
avorable for the group as a whole (88%), as well as individ-
ally, yet as expected, was significantly higher in RC-4
atients (100%) than in RC-5 (83%) patients. When
roader definitions of success were used, the outcome was
C-4) and 5 (RC-5) patients treated with endovascular4 (Rot as positive.
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Volume 53, Number 6 O’Brien-Irr et al 1579SCS was achieved in only 28% of the entire CLI cohort,
with SSCS improving to 52%. These findings were not
surprising; in fact, they are comparable to previous re-
ports4-6 and reaffirm prior concerns that traditional out-
come measures may not address the plethora of issues
encountered by patients with CLI, particularly those with
tissue loss who require prolonged wound care.2-4 Intui-
tively, patients with rest pain should have better outcomes
Table II. Impact of comorbid states on sustained clinical
in Rutherford class 4 (RC-4) and 5 (RC-5) patients throug
Indicator
SCS
RC-4 RC-5
Female gender, % 47 23
Male gender, % 50 14
Pa .9 .32
Hypertension, % 43 19
No hypertension, % 67 25
P .45 .77
CAD, % 33 20
No CAD, % 50 19
P .59 .95
Diabetes mellitus, % 63 10
No diabetes mellitus, % 42 36
P .33 .006
ESRD, % . . . 0
No ESRD, % . . . 24
P . . . .07
CVA, % 50 13
No CVA, % 48 21
P .94 .43
CHF, % 43 9
No CHF, % 50 26
P .75 .09
Hyperlipidemia, % 53 20
No hyperlipidemia, % 36 19
P .39 .95
Current smoker (quit 5 y), % 47 26
Nonsmoker (quit 5 y), % 50 17
P .86 .4
COPD, % 40 24
No COPD, % 50 18
P .69 .63
TASC C/D, % 47 20
TASC A/B, % 0 0
P .2 .33
Multiple segments treated, % 56 21
Single segment treated, % 37 17
P .31 .67
RC-4, % . . . . . .
RC-5, % . . . . . .
P . . . . . .
Index procedure, %
Angioplasty with stent 43 20
Angioplasty only 50 21
Atherectomy 50 15
P .94 .92
Infragenicular intervention, % 63 14
Supragenicular intervention, % 42 26
P .33 .19
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary d
TransAtlantic InterSociety Consensus.
aValues of P  .05 are significant.than those with tissue loss because atherosclerosis, which is pften accompanied by additional comorbidities, is less ad-
anced. Indeed, RC-4 patients had significantly higher ABI
nd were less likely to undergo distal revascularization or
ave DM or ESRD, comorbidities known to be associated
ith poorer outcome.4,6 Sustained clinical success was
hree times more common in RC-4 patients than in RC-5
atients and SSCS was 5.5 times more likely. These data
nmistakably illustrate the need to reassess the common
ss (SCS) and secondary sustained clinical success (SCSS)
variate analysis
SSCS
Overall RC-4 RC-5 Overall
31 79 44 55
22 100 30 46
.39 .16 .25 .38
25 83 39 51
43 100 25 57
.31 .43 .58 .74
22 67 27 33
28 88 41 56
.6 .34 .31 .08
18 88 27 38
38 84 57 67
.04 .83 .014 .005
0 . . . 22 22
31 . . . 41 55
.03 . . . .27 .06
20 100 21 39
29 83 42 55
.41 .37 .15 .23
17 71 21 35
32 90 46 58
.12 .23 .06 .04
29 93 35 52
23 73 43 51
.56 .15 .53 .95
34 83 57 69
23 87 31 42
.22 .81 .05 .01
27 100 54 67
27 82 34 48
1 .3 .19 .16
26 84 39 50
0 100 0 40
.15 .54 .17 .66
30 81 39 50
23 91 36 55
.47 .49 .86 .68
48 . . . . . . 85
21 . . . . . . 39
.006 . . . . . . .001
28 90 40 54
27 79 39 52
20 100 31 40
.82 .61 .84 .64
22 100 29 43
31 79 47 59
.3 .16 .14 .13
CVA, cerebrovascular accident; ESRD, end-stage renal disease; TASC,succe
h bi
isease;ractice of evaluating CLI patients as a single cohort.
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June 20111580 O’Brien-Irr et alSCS was attained in 48% of RC-4 patients, but SSCS
improved dramatically (85%). Although EVI appears to be
clinically advantageous in this group, reintervention was
necessary in 46% to achieve this goal. This may have impor-
tant implications in terms of comparative effectiveness anal-
ysis.
SCS for RC-5 patients was not only significantly lower
than RC- 4 (P  .001) but was dismal (21%). One-third
required reintervention, and still only 50% experienced
complete wound closure, with 44% experiencing delayed
healing. Maintaining skin integrity was also problematic, as
recurrence was noted in 17%. Although SSCS improved in
RC-5 patients, it remained less than favorable for this group
as a whole. Just over one-third of patients healed and
maintained their skin integrity during a 2-year period.
Perhaps even more discouraging is that many required
reintervention, or an average of up to 7 months to accom-
plish this.
Notably, our findings concur with those from Taylor et
al,4 who reported clinical success in 37% of patients with
tissue loss, indicating that patency until wound healing was
the most discriminate indicator of success. Interestingly,
these authors noted that wound healing was significantly
better after open repair than after EVI. Although they
suggested that results were discouraging after either treat-
ment modality, they indicated that a certain degree of
failure to attempt limb salvage might be acceptable because
these patients would otherwise require amputation. Their
amputation rate at 1 year after open revascularization or
EVI was 24%.
However, a study completed by Marsten et al11 on the
natural history of ischemic ulcers not treated by revascular-
ization casts reservation on this perspective, because results
are not that dissimilar from our study or of the study by
Taylor et al. They noted 25% achieved healing at 6 months,
52% by 12 months, and 23% required amputation at 1 year.
The need to distinguish subgroups that will benefit
fromEVI is imperative and is particularly relevant in light of
new findings that have suggested that patients who un-
dergo EVI before bypass may not fare as favorably as those
who proceeded directly to bypass.12
We noted that DM independently predicted failed SCS
Table III. Independent predictors of sustained clinical
success (SCS) and secondary sustained clinical success
(SCSS) and in Rutherford class (RC) 4 and 5 patients
RC Outcome Predictor OR (CI) P
5 SCS DM 3.76 (1.04-13.69) .04
SSCS DM 4.69 (1.42-15.63) .01
CHF 4.07 (0.99-16.67) .05
4 and 5 SCS RC-5 3.01 (1.12-8.13) .029
SSCS DM 2.83 (1.07-7.46) .036
CHF 3.62 (1.19-10.99) .023
RC-5 5.5 (2.40-30.3) .001
CHF, Congestive heart failure; CI, confidence interval; DM, diabetes mel-
litus.in RC-5 patients, whereas DM and CHF were predictors of foor SSCS. Although SSCS was reasonable when neither
omorbidity was present (67%), it was at best mediocre
33%) in those with either CHF or DM and bleak (10%)
hen both occurred. RC-5 patients with DM and CHF
ay not be suitable candidates for EVI. However, it is
ossible that the wounds in this same cohort would never
eal with conservative management nor would they benefit
rom open revascularization. Additional investigation is
arranted.
Patient selection is a critical precept to improving out-
ome. Rutherford class was the only factor that indepen-
ently predicted both SCS and SSCS among patients with
LI. Refining patient selection can improve outcome.
SCS was achieved in 94% of RC-4 patients who had
either DM nor CHF but in only 10% of RC-5 patients
ith both comorbidities. Interestingly, smoking was para-
oxically associated with improved SSCS on bivariate but
ot multivariate analysis. We believe this occurred because
mokers were less likely to be diabetic and significantly less
ikely to have CHF, both of which ultimately emerged as
ndependent predictors of poor SSCS. The link between
moking and peripheral arterial disease (PAD) complica-
ions and mortality has been well established. Recent stud-
es have reported contrary findings, however. Luo et al13
ound that smoking did not contribute to mortality in PAD
atients, and Hoogwegt et al14 noted that cessation had no
ffect on quality of life in PAD patients who had undergone
ascular surgery. Despite those findings, authors from both
tudies indicated that smoking cessation should remain a
arget for intervention.13,14
This study was limited by its retrospective design and
ample size. Although recommended reporting standards
ere used,10 the inherent definition of success creates bias
n favor of RC-4 patients, who are considered clinically
uccessful when improvement by one category is achieved.
his contrasts sharply with RC-5 patients, who require
omplete wound healing or improvement by two catego-
ies to be considered clinically successful.
Moreover, comparative analysis with other studies may
e difficult because we incorporated time horizons for
ealing as well as the absence of recurrent tissue loss into
he operational definition of success to provide a more
lobal evaluation of wound healing because these issues
ave been identified as problematic for CLI patients.2-4
Understanding the role that other etiologic factors,
uch as diabetic neuropathy, osteomyelitis, stasis disease,
nd location and severity of tissue loss play upon wound
ealing as well as the effect of various treatment modalities
ould have been beneficial. Very complex relationships
ikely exist, and unfortunately, that assessment was beyond
he scope of this study.
Evaluation of ambulatory status may also have been
aluable, as others have indicated that it is an important
eterminant of success.4,6 Unfortunately, this was unavail-
ble. It is important that these data be incorporated into
uture research.
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Comprehensive analysis is imperative to guide treat-
ment strategies and is particularly relevant given the current
climate of health care reform in which lower extremity PAD
has been recognized as a priority in the national health
initiative on comparative research.15 Use of EVI in the
treatment of CLI continues to expand at a rapid pace, yet
research with meaningful traditional and patient-centered
outcomes measured in tandem by diagnosis has been lim-
ited. Studies that have been completed have suggested that
success has been less than favorable. We found that patients
with rest pain differ significantly from those with tissue loss,
so each patient should be evaluated individually by Ruth-
erford class. Excellent outcome can be achieved through
fastidious patient selection; specifically, RC-4 patients with-
out DM or CHF, whereas RC-5, CHF, and DM predict
relatively poor outcome. The ability to identify patients
who will benefit from EVI can facilitate appropriate alloca-
tion of limited resources. Further research should be di-
rected toward this effort.
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